most effective glp-1 for obesity treatment 2025 Outlook in 2025: more than a transition year GLP-1 Agonists For Obesity In

They have been urging wholesalers to distribute the initial limited stock of Ozempic or other GLP-1 treatments equitably throughout Australia, including remote and rural areas that may face challenges in accessing them during periods of national supply shortage

However, it must be used solely for scientific investigation and cannot be marketed for human use or with any therapeutic claims

10.1097/MCO.0000000000000574 20

The American Diabetes Association Standards of Care do not include berberine in evidence-based treatment algorithms, and patients with type 2 diabetes should not discontinue prescribed medications in favor of supplements without medical supervision